IL2 and melanoma: For advanced melanoma patients who have failed ICIs treatment, TIL therapy (intravenous high-dose IL-2) has shown clinical activity in different subtypes (mucosal, superficial diffusion, and limb), but there are reversible AEs of grade 3 and grade 4 (56).